You are here: Home » News-CM » Equities » Hot Pursuit
Business Standard

Glenmark Pharma sizzles on securing marketing authorization

Capital Market 

Pharmaceuticals rose 2.26% to Rs 698.70 at 11:40 IST on after the company announced that it has secured marketing authorization in for its generic version of

The announcement was made during market hours today, 10 September 2018.

Meanwhile, the Sensex was down 265.30 points, or 0.69% to 38,124.52

On the BSE, 1.45 lakh shares were traded in the counter so far compared with average daily volumes of 74,000 shares in the past two weeks. The stock had hit a high of Rs 711.55 and a low of Rs 685 so far during the day.

Pharmaceuticals announced today that its subsidiary Arzneimittel GmbH has secured marketing authorization in for Fluticasone/dry powder (DPI), a generic version of GlaxoSmithKline's Fluticasone/is a for the treatment of and (COPD). Glenmark will sell the product in under the name SALFLUTIN.

Glenmark had entered into a strategic development and licensing agreement with (Celon) in 2015 to develop and market generic Fluticasone/in 15 European countries. The company has already launched this product in Denmark, and According to IQVIA data, Fluticasone/Salmeterol dry powder (DPI) had sales of $844 million in in the 12 month period ended March 2018.

is a research-driven, global,

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Mon, September 10 2018. 11:46 IST